Philips is a global health-technology company with reported sales of EUR 18,021 million in 2024. These Philips statistics cover company sales, segment trends, profitability, adjusted measures, workforce, research and development, geographic groupings, restructuring and Respironics-related costs, with periods and definitions stated explicitly.
Key Philips Statistics
The following highlights summarize the most useful figures across the available Philips data:
- In 2024, Philips Group sales were EUR 18,021 million worldwide.
- In 2023, Philips Group sales were EUR 18,169 million worldwide.
- In 2022, Philips Group sales were EUR 17,827 million worldwide.
- In 2024, Diagnosis & Treatment sales were EUR 8,790 million for the reportable segment.
- In 2024, Connected Care sales were EUR 5,134 million for the reportable segment.
- In 2024, Personal Health sales were EUR 3,486 million for the reportable segment.
- In 2024, Philips Group income from operations was EUR 529 million, equal to 3% of sales.
- In 2024, Personal Health income from operations was EUR 544 million, or 16% of segment sales.
- In 2024, Philips Group adjusted EBITA was EUR 2,077 million.
- In 2024, Philips Group adjusted EBITA margin was 11.5% of sales.
- In 2024, Philips Group adjusted EBITDA was EUR 2,982 million.
- In 2024, free cash flow was EUR 0.9 billion for Philips Group.
- At December 31, 2024, Philips had 66,116 payroll employees measured in FTEs.
- At December 31, 2024, Philips had 10,843 research-and-development FTEs.
- In 2024, Philips sales and services reached more than 100 countries.
- In 2024, growth geographies generated EUR 4,863 million of sales under Philips-defined groupings.
- In 2024, restructuring charges were EUR 268 million for Philips Group.
- In 2024, Respironics-related charges totaled EUR 691 million under Philips’ reported definition.
Contents
- Philips sales and segment trends
- Philips operating profit and margins
- Philips adjusted EBITA and EBITDA
- Philips employees and R&D scale
- Philips geography and sales reach
- Philips restructuring and Respironics costs
Philips Sales and Segment Trends
Philips Group sales were EUR 17,827 million in 2022, EUR 18,169 million in 2023 and EUR 18,021 million in 2024. These are annual-report sales figures for the Philips Group, reported in millions of euros.
| Philips business | 2022 sales | 2023 sales | 2024 sales |
|---|---|---|---|
| Diagnosis & Treatment | EUR 8,303 million | EUR 8,825 million | EUR 8,790 million |
| Connected Care | EUR 5,268 million | EUR 5,138 million | EUR 5,134 million |
| Personal Health | EUR 3,626 million | EUR 3,602 million | EUR 3,486 million |
| Philips Group | EUR 17,827 million | EUR 18,169 million | EUR 18,021 million |
Source: Philips Full Annual Report 2024. Segment figures are reportable-segment measures, not product-level or sleep-market sales, and the report also includes an Other category.
For 2024 compared with 2023, nominal sales growth was 0% in Diagnosis & Treatment, 0% in Connected Care and -3% in Personal Health. On Philips’ comparable-sales measure, growth was 1% for Diagnosis & Treatment, 2% for Connected Care and -1% for Personal Health.
Comparable sales is a non-IFRS measure, so it should not be treated as identical to nominal reported sales or assumed to have the same standardized meaning as an IFRS measure.
Philips Operating Profit and Margins
Reported operating results show a change at Group level between 2023 and 2024. Philips Group income from operations was a EUR 115 million loss, or -1% of sales, in 2023, compared with EUR 529 million, or 3% of sales, in 2024.
The 2024 segment results were mixed, with positive reported income from operations in Diagnosis & Treatment and Personal Health and a reported loss in Connected Care:
- Diagnosis & Treatment recorded EUR 592 million of income from operations in 2024, equal to 7% of segment sales.
- Connected Care recorded a EUR 466 million loss from operations in 2024, equal to -9% of segment sales.
- Personal Health recorded EUR 544 million of income from operations in 2024, equal to 16% of segment sales.
Source: Philips Full Annual Report 2024. These are reported operating results and margins, not adjusted measures.
The fourth quarter of 2024 provides a separate quarterly view. Philips Group’s adjusted EBITA margin was 13.5%, while Diagnosis & Treatment recorded 12.1% and Connected Care 15.0% for the same quarter.
Source: Philips announces its 2024 Fourth-Quarter and Annual Results. Quarterly adjusted EBITA margins are non-IFRS measures and should not be directly substituted for annual reported operating margins.
Philips Adjusted EBITA and EBITDA Data
Philips’ adjusted measures provide a management-reported view that differs from IFRS income from operations. The company states that adjusted EBITA, adjusted EBITDA and comparable sales growth are non-IFRS measures without standardized IFRS meaning, and they may not be comparable with measures used by other issuers.
| Measure | 2023 | 2024 |
|---|---|---|
| Group adjusted EBITA | EUR 1,921 million | EUR 2,077 million |
| Group adjusted EBITA margin | 10.6% | 11.5% |
| Group adjusted EBITDA | EUR 2,845 million | EUR 2,982 million |
Source: Philips Full Annual Report 2024. Amounts are reported in millions of euros unless otherwise stated.
In 2024, segment adjusted EBITA was EUR 1,018 million for Diagnosis & Treatment, EUR 494 million for Connected Care and EUR 584 million for Personal Health. Their adjusted EBITA margins were 11.6%, 9.6% and 16.8%, respectively.
The comparable 2023 segment figures were EUR 1,028 million and 11.6% for Diagnosis & Treatment, EUR 369 million and 7.2% for Connected Care, and EUR 597 million and 16.6% for Personal Health.
Group adjusted EBITDA was EUR 2,044 million in 2022, EUR 2,845 million in 2023 and EUR 2,982 million in 2024. Segment adjusted EBITDA in 2024 was EUR 1,219 million for Diagnosis & Treatment, EUR 747 million for Connected Care and EUR 679 million for Personal Health, compared with EUR 1,241 million, EUR 623 million and EUR 698 million, respectively, in 2023.
Philips also reported EUR 0.9 billion of free cash flow for full-year 2024. The company’s official results release identifies this as a non-IFRS measure.
Source: Philips announces its 2024 Fourth-Quarter and Annual Results.
Philips Employees and R&D Scale
Philips had 73,941 employees at December 31, 2022, 67,493 at December 31, 2023 and 66,116 at December 31, 2024. These are year-end payroll personnel counts measured in FTEs, so they differ from average employment and from third-party worker totals.
At the end of 2024, the company reported 10,843 research-and-development FTEs and 27,478 production FTEs. It also reported 1,708 third-party workers hired through companies; those workers were not Philips payroll employees.
Philips’ average employment across all geographies was 68,956 FTEs in 2024, while average employment in the Netherlands was 8,844 FTEs. The average geographic measures should not be read as December 31 headcounts.
Source: Philips Full Annual Report 2024.
A 2023 strategy announcement set forward-looking research targets rather than reporting completed outcomes. Philips planned to invest 9% of sales in R&D, described as more than EUR 1.7 billion, and planned to place 90% of R&D resources in the businesses, compared with 70% in 2022.
Source: Philips presents its plan to create value with sustainable impact. These figures are management plans or targets and are labeled forecasts, not observed results.
Philips Geography and Sales Reach
Philips reported sales and services in more than 100 countries in 2024. This is a threshold in the company’s description, not an exact country count.
The annual report divides markets into Philips-defined mature and growth geographies. In 2024, mature geographies generated EUR 13,159 million of sales and growth geographies generated EUR 4,863 million.
| Philips-defined geography | 2024 sales | 2024 comparable sales growth versus 2023 |
|---|---|---|
| Mature geographies | EUR 13,159 million | 2% |
| Growth geographies | EUR 4,863 million | -2% |
Source: Philips Full Annual Report 2024. These are company-defined geography groups, not universal statistical classifications, and comparable sales growth is non-IFRS.
The geographic figures provide scale and direction for Philips’ own market groupings, but they do not establish product adoption, customer counts or sleep-market participation. They also should not be interpreted as a standardized country classification.
Philips Restructuring and Respironics-Related Costs
Philips recorded EUR 285 million of restructuring charges in 2023 and EUR 268 million in 2024. Within the 2024 total, EUR 106 million related to personnel lay-off costs and EUR 134 million related to restructuring-related asset impairment.
Source: Philips Full Annual Report 2024. These are reported restructuring charges for the Philips Group.
Respironics-related charges were EUR 1,162 million in 2023 and EUR 691 million in 2024. Philips defines this grouping as including litigation, consent-decree, field-action and related items.
The 2024 components reported by Philips included a EUR 984 million Respironics litigation provision and EUR 538 million of insurance income shown as an offset. Consent-decree charges were EUR 113 million, while field-action running costs were EUR 133 million.
Source: Philips Full Annual Report 2024. The components are separate reported items, and insurance income is an offset rather than another charge.
Because the annual report uses specific accounting and company-defined groupings, these figures should be read as Philips-reported costs for the stated periods. They are not estimates of total future liability, consumer harm, product adoption or the performance of the broader sleep market.